FREMONT, Calif., July 31 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc.
(Nasdaq: PDLI) today announced that Joseph Klein III, also known as Skip,
has been unanimously elected to serve on the company's board of directors.
Klein's election to the board comes after a months-long process of
identifying and evaluating numerous potential candidates.
"After conducting a broad and comprehensive search supported by an
outside search firm, the board has elected Skip Klein, a widely experienced
and deeply respected institutional investor who offers nearly 20 years of
biopharmaceutical industry and financial expertise," said L. Patrick Gage,
Ph.D., the company's chairman of the board. "A board member of Skip's
caliber with broad experience will bring added strength to PDL, and we look
forward to his contributions as a new member of PDL's board of directors."
"Since I first met management during PDL's road show for its IPO in
1992, I have closely watched and analyzed the company's progress. PDL has
an exceptionally well-validated technology platform; indeed, many of
biotech's most important commercial antibodies have benefited from the
application of PDL technology. With focused, disciplined clinical
development of its exciting proprietary pipeline, I am convinced that PDL
will follow in the footsteps of other successful commercial biotech
companies," said Skip Klein. "After meeting with every member of the Board
and several members of management, I hope to be able to bring value-added
insights and investor perspectives to the already strong capabilities of
this group of fine people. I am convinced that everyone shares the goal of
building meaningful shareholder value over the next five years and beyond."
Klein currently serves as Managing Director of Gauss Capital Advisors,
LLC, a financial consulting and investment advisory firm focused on
biopharmaceuticals, which he founded in March 1998. Since September 2003,
Mr. Klein has also served as a Venture Partner of Red Abbey Venture
Partners, LP, a life sciences private equity fund. From September 2001 to
September 2002, Mr. Klein was a Venture Partner of MPM Capital, a
healthcare venture capital firm. Mr. Klein served as Vice President,
Strategy, for Medical Manager Corporation, a leading developer of physician
office management information systems, from June 1999 until it merged with
WebMD Corporation in September 2000. In the 10 years prior to joining
Medical Manager Corporation, Mr. Klein was a portfolio manager and
securities analyst at T. Rowe Price Associates, Inc. and The Kaufmann Fund,
Inc. Mr. Klein serves on the Board of Directors of four publicly traded
biopharmaceutical companies: BioMarin Pharmaceutical Inc., Isis
Pharmaceuticals, Inc., OSI Pharmaceuticals, Inc. and Savient
Pharmaceuticals, Inc. Mr. Klein received a B.A. in economics from Yale
University and an M.B.A. from the Stanford Graduate School of Business.
About PDL BioPharma
PDL BioPharma, Inc. is a biopharmaceutical company focused on
discovering, developing and commercializing innovative therapies for severe
or life-threatening illnesses. Commercially focused in the acute-care
hospital setting, PDL markets and sells its portfolio of products in the
United States and Canada. A pioneer of antibody humanization technology,
PDL promotes this technology through licensing agreements and clinical
development of its own diverse pipeline of investigational compounds. PDL's
research platform centers on the discovery and development of antibodies to
treat cancer and autoimmune diseases. For more information, please visit
http://www.pdl.com.
Forward-looking Statements
The information in this press release should be considered accurate
only as of the date of this press release. PDL has no intention of updating
and specifically disclaims any duty to update the information in this press
release for any reason, except as required by law, even as new information
becomes available or other events occur in the future. This press release
contains "forward-looking statements" that are based on current
expectations and assumptions that are subject to risks and uncertainties.
The actual results may differ materially from those in the forward-looking
statements because of various factors, risks and uncertainties. For further
information regarding factors, risks and uncertainties that may cause such
differences, please refer to the filings PDL has made with the Securities
and Exchange Commission, including the "Risk Factors" sections of PDL's
Quarterly and Annual Reports, copies of which may be obtained at the
"Investors" section on PDL's website at http://www.pdl.com. All
forward-looking statements in this press release are qualified in their
entirety by this cautionary statement.
SOURCE PDL BioPharma, Inc.
 back to top
Related links:
http://www.pdl.com
CONTACT:
Ami Knoefler, Corporate and Investor
Relations, +1-510-284-8851, ami.knoefler@pdl.com, or Kathleen
Rinehart, Corporate Communications, +1-510-574-1480,
kathleen.rinehart@pdl.com, both of PDL BioPharma, Inc.
|
